Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(10):864–870. doi: 10.1111/j.1349-7006.2003.tb01368.x

Ubiquitin‐immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer

Keiichi Iwaya 1, Hitoshi Ogawa 1, Yasuo Mukai 1, Akihiro Iwamatsu 2, Kiyoshi Mukai 1,✉
PMCID: PMC11160294  PMID: 14556659

Abstract

Decreased amounts of cytokeratin (CK) 8/18 in the cytoplasm of breast cancer cells correlate with a poor prognosis. Although such decreases have been attributed to suppressed gene expression, accelerated protein degradation may also be responsible. In order to investigate whether selective degradation via the ubiquitin (Ub)‐dependent proteasome pathway occurs in breast cancer, one‐ and two‐dimensional (1‐D and 2‐D) immunoblot analysis was performed on cancerous and normal breast tissue from 50 breast cancer patients using the anti‐Ub monoclonal antibodies (mAbs) KM691 and KM690. On 1‐D gel electrophoresis, one broad band or two bands were detected at about 43 kDa; these were detected only in cancer tissue. Immunoreactive bands at 43 kDa were significantly associated with aggressive morphology (P=0.011), nuclear p53 accumulation (P=0.015) and overexpression of Her2/neu protein (P=0.012). On 2‐D gel electrophoresis, these bands were fractionated into a group of several spots that formed a staircase pattern at 40–45 kDa. Partial amino acid sequencing analysis demonstrated that these Ub‐immunoreactive spots corresponded to CK8 and CK18; however, since they did not have an amino‐terminal domain, and were located at lower molecular weight positions than intact CK8 and CK18 on the 2‐D gel, they were regarded as degradation products. CK18 degradation was confirmed by confocal microscopy as loss of the frame‐like network that forms the luminal structure. These results indicate that CK 8/18 degradation products are detected specifically in breast cancer and may determine its aggressiveness.

References

  • 1. Ozkaynak E, Finley D, Varshavsky A. The yeast ubiquitin gene: head‐to‐tail repeats encoding a polyubiquitin precursor protein. Nature 1984; 312: 663–6. [DOI] [PubMed] [Google Scholar]
  • 2. Hershko A, Ciechanover A, Varshavsky A. Basic Medical Research Award. The ubiquitin system. Nat Med 2000; 6: 1073–81. [DOI] [PubMed] [Google Scholar]
  • 3. Hershko A, Leshinsky E, Ganoth D, Heller H. ATP‐dependent degradation of ubiquitin‐protein conjugates. Proc Natl Acad Sci USA 1984; 81: 1619–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Bachmair A, Varshavsky A. The degradation signal in a short‐lived protein. Cell 1989; 56: 1019–32. [DOI] [PubMed] [Google Scholar]
  • 5. Ciechanover A, Orian A, Schwartz AL. Ubiquitin‐mediated proteolysis: biological regulation via destruction. Bioassays 2000; 22: 442–51. [DOI] [PubMed] [Google Scholar]
  • 6. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A. Identification of the von Hippel‐Lindau tumor‐suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999; 96: 12436–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Ishibashi Y, Takada K, Joh K, Ohkawa K, Aoki T, Matsuda M. Ubiquitin immunoreactivity in human malignant tumours. Br J Cancer 1991; 63: 320–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Osada T, Sakamoto M, Nishibori H, Iwaya K, Matsuno Y, Muto T, Hirohashi S. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. J Hepatol 1997; 26: 1266–73. [DOI] [PubMed] [Google Scholar]
  • 9. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequence‐specific DNA‐binding protein. Science 1991; 252: 1708–11. [DOI] [PubMed] [Google Scholar]
  • 10. Lowe SW, Ruley HE, Jacks T, Housman DE. p53‐dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–67. [DOI] [PubMed] [Google Scholar]
  • 11. El‐Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–25. [DOI] [PubMed] [Google Scholar]
  • 12. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000; 103: 321–30. [DOI] [PubMed] [Google Scholar]
  • 13. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993; 72: 3641–7. [DOI] [PubMed] [Google Scholar]
  • 15. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node‐negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13: 821–30. [DOI] [PubMed] [Google Scholar]
  • 16. Iwaya K, Tsuda H, Fukutomi T, Tsugane S, Suzuki M, Hirohashi S. Histologic grade and p53 immunoreaction as indicators of early recurrence of node‐negative breast cancer. Jpn J Clin Oncol 1997; 27: 6–12. [DOI] [PubMed] [Google Scholar]
  • 17. Iwaya K, Tsuda H, Fujita S, Suzuki M, Hirohashi S. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues. Lab Invest 1995; 72: 707–14. [PubMed] [Google Scholar]
  • 18. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6‐immortalized human mammary epithelial cells. J Virol 1991; 65: 6671–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296–9. [DOI] [PubMed] [Google Scholar]
  • 20. Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y. The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986; 125: 431–5. [PMC free article] [PubMed] [Google Scholar]
  • 21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology 1991; 19: 403–10. [DOI] [PubMed] [Google Scholar]
  • 22. Bradford MM. A rapid and sensitive method for the quantities of microgram quantities of protein utilizing the principle of protein‐dye binding. Anal Biochem 1976; 72: 248–54. [DOI] [PubMed] [Google Scholar]
  • 23. Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N, Ichihara A. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991; 51: 6677–85. [PubMed] [Google Scholar]
  • 24. Nishibori H, Matsuno Y, Iwaya K, Osada T, Kubomura N, Iwamatsu A, Kohno H, Sato S, Kitajima M, Hirohashi S. Human colorectal carcinomas specifically accumulate Mr 42,000 ubiquitin‐conjugated cytokeratin 8 fragments. Cancer Res 1996; 56: 2752–7. [PubMed] [Google Scholar]
  • 25. Iwamatsu A. S‐Carboxymethylation of proteins transferred onto polyvinylidene difluoride membranes followed by in situ protease digestion and amino acid microsequencing. Electrophoresis 1992; 13: 142–7. [DOI] [PubMed] [Google Scholar]
  • 26. Aebersold RH, Leavitt J, Saavedra RA, Hood LE, Kent SB. Internal amino acid sequence analysis of proteins separated by one‐ or two‐dimensional gel electrophoresis after in situ protease digestion on nitrocellulose. Proc Natl Acad Sci USA 1987; 84: 6970–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. Identifying proteins from two‐dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 1993; 90: 5011–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90: 1601–8. [DOI] [PubMed] [Google Scholar]
  • 29. Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997; 138: 1379–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Ku NO, Omary MB. Keratins turn over by ubiquitination in a phosphorylation modulated fashion. J Cell Biol 2000; 149: 547–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Chen PH, Ornelles DA, Shenk T. The adenovirus L323‐kilodalton proteinase cleaves the amino‐terminal head domain from cytokeratin 18 and disrupts the cytokeratin network of HeLa cells. J Virol 1993; 67: 3507–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Breitkreutz D, Boukamp P, Ryle CM, Stark HJ, Roop DR, Fusenig NE. Epidermal morphogenesis and keratin expression in c‐Ha‐ras‐transfected tumorigenic clones of the human HaCaT cell line. Cancer Res 1991; 51: 4402–9. [PubMed] [Google Scholar]
  • 33. Paine TM, Fontanini G, Basolo F, Geronimo I, Elliott JW, Russo J. Mutated c‐Ha‐ras oncogene alters cytokeratin expression in the human breast epithelial cell line MCF‐10A. Am J Pathol 1992; 140: 1483–8. [PMC free article] [PubMed] [Google Scholar]
  • 34. Dairkee S, Heid HW. Cytokeratin profile of immunomagnetically separated epithelial subsets of the human mammary gland. In Vitro Cell Dev Biol Anim 1993; 29A: 427–32. [DOI] [PubMed] [Google Scholar]
  • 35. Dairkee SH, Puett L, Hackett AJ. Expression of basal and luminal epithelium‐specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst 1988; 80: 691–5. [DOI] [PubMed] [Google Scholar]
  • 36. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998; 433: 119–29. [DOI] [PubMed] [Google Scholar]
  • 37. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996; 2: 1879–85. [PubMed] [Google Scholar]
  • 38. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen‐Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747–52. [DOI] [PubMed] [Google Scholar]
  • 39. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen‐Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratin 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Bader BL, Magin TM, Freudenmann M, Stumpp S, Franke WW. Intermediate filaments formed de novo from tail‐less cytokeratins in the cytoplasm and in the nucleus. J Cell Biol 1991; 115: 1293–307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Franke WW, Schmid E, Wellsteed J, Grund C, Gigi O, Geiger B. Change of cytokeratin filament organization during the cell cycle: selective masking of an immunologic determinant in interphase PtK2 cells. J Cell Biol 1983; 97: 1255–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis. J Pathol 1999; 187: 567–72. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES